Enliven Therapeutics Inc · Q4 2020 earnings

Briefing

Imara Inc. reported financial results for the year ended December 31, 2020, and reviewed recent business highlights.

Imara Inc. reported a net loss attributable to common stockholders of $49.2 million, or $3.53 per share, for the year ended December 31, 2020. The company's cash, cash equivalents, and investments totaled $88.2 million as of December 31, 2020. Research and development expenses were $32.2 million, and general and administrative expenses were $9.5 million for the year ended December 31, 2020.

• Advanced IMR-687 into global Phase 2b clinical trials for sickle cell disease and beta-thalassemia.
• Reported clinical data supporting IMR-687 as a novel treatment for sickle cell disease and were granted important regulatory designations for IMR-687.
• Successfully completed an initial public offering, raising gross proceeds of $86.5 million.
• Expanded leadership team with the appointments of Kenneth Attie, M.D. as Senior Vice President and Chief Medical Officer and Lynette Hopkinson as Senior Vice President of Regulatory.

Headline financials

Revenue & EPS history

Imara expects full-year 2021 research and development expenses to range between $50 million and $55 million and full-year 2021 general and administrative expenses to range between $12 million and $14 million. The company expects that its cash, cash equivalents and investments as of December 31, 2020, will be sufficient to enable it to fund its planned operations into mid-2022.